Daiichi Sankyo Announces Landmark Clinical Trial Results for ENHERTU and DATROWAY Across Multiple Cancer Types at ESMO 2025
Daiichi Sankyo Co. Ltd. will present new clinical research from its DXd antibody drug conjugate portfolio at the 2025 ESMO Congress. Key highlights include late-breaking presentations of ENHERTU from the DESTINY-Breast11 and DESTINY-Breast05 phase 3 trials, focusing on HER2 positive early breast cancer, and data from the TROPION-Breast02 study on DATROWAY for metastatic triple negative breast cancer. Additional results from early phase trials will also be showcased.
Daiichi Sankyo Co. Ltd. announced that it will present new clinical research from its DXd antibody drug conjugate (ADC) portfolio at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The company will feature four late-breaking presentations, including back-to-back Presidential Symposium presentations of ENHERTU from the DESTINY-Breast11 and DESTINY-Breast05 phase 3 trials, highlighting its potential use in HER2 positive early breast cancer. Additionally, late-breaking data from the TROPION-Breast02 study will be presented, evaluating DATROWAY in first-line metastatic triple negative breast cancer. Other presentations will include initial results from ongoing early phase trials such as DS-3939 in advanced solid tumors and sub-studies of TROPION-PanTumor03. Results from these studies will be presented at ESMO 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013032388) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
